Did you know? EGFR is a gene found in cells that is important for cell growth and survival. In some people, the EGFR gene begins to mutate or change, which can be a driving cause of cancer. There are [...]
Did you know? There are different kinds of changes, called mutations, that can happen in the MET gene. These changes can help cancer grow and spread. One type is called c-MET overexpression. This means the cancer cells make too [...]
Author: Matthew Reiss, MSE, PhD, Manager, Precision Medicine & Navigation, GO2 for Lung Cancer Question: Why does it take so long for the FDA to approve new drugs? Answer: Whenever a new cancer drug is created, it [...]
Question: I’d like to start looking at whether a clinical trial might be good for me, but the process seems overwhelming. Where should I start? What are the best resources for me to understand my options? Answer: Whenever you [...]
On Dec. 18, 2024, the U.S. Food and Drug Administration (FDA) approved Ensacove (ensartinib) for people with locally advanced or metastatic non-small cell lung cancer (NSCLC) who have an ALK mutation and have not previously received an ALK-targeted therapy. [...]
On Dec. 4, 2024, the U.S. Food and Drug Administration (FDA) granted accelerated approval of Bizengri (zenocutuzumab-zbco) for people with metastatic non-small cell lung cancer (NSCLC) who have an NRG1 mutation following progression on or after prior systemic therapy. [...]
On December 4, 2024, the U.S. Food and Drug Administration (FDA) approved the use of Imfinzi (durvalumab) for adults with limited-stage small cell lung cancer (LS-SCLC) whose disease did not progress following combination platinum-based chemotherapy and radiation. Previously approved [...]
Grace M. resides in Arlington, VA with her incredibly supportive husband and near her parents, with whom she is very close. She loves to host her family and friends so that she can experiment with new, intricate recipes and [...]
Matthew Reiss MSE PhD, Manager, Precision Medicine & Navigation, GO2 for Lung Cancer, and Jared Weiss MD, Section Chief of Thoracic and Head & Neck Oncology, Professor of Medicine, University of North Carolina at Chapel Hill It is [...]
On October 15, 2024, the U.S. Food and Drug Administration (FDA) approved the use of a wearable treatment device, Optune Lua, in combination with PD-1/PD-L1 immunotherapies or the chemotherapy docetaxel for people with metastatic non-small cell lung cancer (NSCLC) [...]